Form 8-K - Current report:
SEC Accession No. 0001999371-25-005877
Filing Date
2025-05-12
Accepted
2025-05-12 16:45:36
Documents
14
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_051225.htm   iXBRL 8-K 24225
2 PRESS RELEASE ex99-01.htm EX-99.01 72466
  Complete submission text file 0001999371-25-005877.txt   287060

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tnxp-20250512.xsd EX-101.SCH 3023
4 XBRL LABEL FILE tnxp-20250512_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE tnxp-20250512_pre.xml EX-101.PRE 24170
16 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_051225_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 25935604
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)